Lixte Biotechnology Holdings Inc (LIXT)

$2.39

+0.05

(+2.03%)

Market is closed - opens 7 PM, 25 Jul 2024

Performance

  • $2.39
    $2.53
    $2.39
    downward going graph

    0.1%

    Downside

    Day's Volatility :5.63%

    Upside

    5.53%

    downward going graph
  • $1.58
    $4.73
    $2.39
    downward going graph

    33.89%

    Downside

    52 Weeks Volatility :66.6%

    Upside

    49.47%

    downward going graph

Returns

PeriodLixte Biotechnology Holdings IncIndex (Russel 2000)
3 Months
-28.66%
0.0%
6 Months
25.8%
0.0%
1 Year
-42.36%
0.0%
3 Years
-91.52%
-19.9%

Highlights

Market Capitalization
5.2M
Book Value
- $0.17
Earnings Per Share (EPS)
-2.27
PEG Ratio
0.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-73.97%
Return On Equity TTM
-130.17%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
-2.27
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Technicals Summary

Sell

Neutral

Buy

Lixte Biotechnology Holdings Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings Inc
-6.4%
25.8%
-42.36%
-91.52%
-93.74%
Moderna, Inc.
Moderna, Inc.
-11.5%
19.92%
-1.43%
-63.9%
737.94%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.78%
11.32%
45.17%
82.69%
236.57%
Novo Nordisk A/s
Novo Nordisk A/s
-6.33%
26.68%
64.47%
198.6%
438.18%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.24%
14.68%
37.33%
146.48%
182.87%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings Inc
NA
NA
0.0
0.0
-1.3
-0.74
NA
-0.17
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.55
31.55
1.46
44.35
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.95
45.95
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.16
32.16
0.53
17.04
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings Inc
NA
$5.2M
-93.74%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.9B
737.94%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.9B
236.57%
31.55
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.6B
438.18%
45.95
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.0B
182.87%
32.16
39.46%

Insights on Lixte Biotechnology Holdings Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 64.5% return, outperforming this stock by 106.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 193.7% return, outperforming this stock by 285.3%

Institutional Holdings

  • HighTower Advisors, LLC

    4.42%
  • Ethos Financial Group LLC

    1.10%
  • Morgan Stanley - Brokerage Accounts

    0.32%
  • Tower Research Capital LLC

    0.18%
  • FNY Investment Advisers, LLC

    0.13%

Company Information

lixte biotechnology holdings, inc. (lixte) is a clinical-stage public (lixt) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. the current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and dna damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. the phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. the lead compound lb-100 is in phase i trial and has the potential to be first-in-class. the deacetylase in

Organization
Lixte Biotechnology Holdings Inc
Employees
3
CEO
Mr. Bastiaan van der Baan M.Sc.
Industry
Biotechnology

FAQs